Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,334JPY
2:00am EDT
Change (% chg)

¥16 (+0.30%)
Prev Close
¥5,318
Open
¥5,321
Day's High
¥5,343
Day's Low
¥5,296
Volume
1,580,800
Avg. Vol
2,066,713
52-wk High
¥5,527
52-wk Low
¥4,098

4502.T

Chart for 4502.T

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.70
Market Cap(Mil.): ¥4,203,992.00
Shares Outstanding(Mil.): 790.52
Dividend: 90.00
Yield (%): 3.38

Financials

  4502.T Industry Sector
P/E (TTM): 31.59 29.15 30.10
EPS (TTM): 168.35 -- --
ROI: 4.33 13.65 13.21
ROE: 6.48 14.61 14.37

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday: ** Sibanye Gold's shareholders approved the South African miner's $2.2 billion buyout of U.S.-based Stillwater Mining < SWC.N>, moving it a step closer to significantly boosting its platinum portfolio. ** Israel Chemicals has agreed to sell its 50 percent stake in water desalination firm IDE Technologies for about $180 million, a leading Israeli financial news website reported

6:30am EDT

J&J, Takeda among interested in Brazil's Hypermarcas: sources

SAO PAULO Johnson & Johnson , Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA , two people with knowledge of the matter said on Monday.

Apr 24 2017

UPDATE 4-J&J, Takeda among interested in Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA , two people with knowledge of the matter said on Monday.

Apr 24 2017

J&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday.

Apr 24 2017

Takeda's largest study brings dengue vaccine step closer

Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business.

Apr 05 2017

Takeda's largest study brings dengue vaccine step closer

April 5 Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business.

Apr 05 2017

BRIEF-Finch Therapeutics, Takeda collaborate to develop microbiome therapeutics in inflammatory bowel disease

* Finch Therapeutics and Takeda announce global collaboration to develop microbiome therapeutics in inflammatory bowel disease (ibd)

Apr 05 2017

BRIEF-Takeda Pharmaceutical forms drug development company with two partners - Nikkei

* Takeda pharmaceutical formed 10 billion yen ($87.2 million) drug development company with two partners

Mar 14 2017

BRIEF-R&I removes Takeda Pharmaceutical from rating monitor and downgrades rating to "AA-" – R&I

* Rating and Investment Information, Inc. (R&I) removed the co from rating monitor - R&I

Mar 01 2017

Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study

Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.

Feb 28 2017

More From Around the Web

Earnings vs. Estimates